A na-eji Relugolix agwọ ọrịa kansa prostate na ụmụ nwoke.
Aha ika: Orgovyx
Klas ọgwụ ọjọọ: Antineoplastic - LHRH (GnRH) Ndị na-emegide Pituitary Suppressants
Nnweta: Achọrọ ndenye ọgwụ
Ime ime: Gwa dọkịta gị.Ọgwụ a nwere ike imebi nwa e bu n'afọ.
Lactation: kpọtụrụ dọkịta tupu iji

Relugolix bụ homonụ na-ewepụta gonadotropin na-abụghị peptide (GnRH ma ọ bụ luteinizing hormone na-ahapụ homonụ (LHRH), nke nwere ọrụ antineoplastic.Relugolix na-ejikọta ma na-egbochi GnRH nnabata na pituitary gland, nke ma na-egbochi GnRH njikọ na GnRH receptor ma na-egbochi nzuzo na ntọhapụ nke ma luteinizing hormone (LH) na follicle stimulating hormone (FSH).N'ime ụmụ nwoke, mgbochi nke nzuzo nzuzo LH na-egbochi ntọhapụ nke testosterone site na mkpụrụ ndụ Leydig na testes.Ebe ọ bụ na a chọrọ testosterone iji kwado uto prostate, ibelata ọkwa testosterone nwere ike igbochi mmụba cell prostate na-adabere na hormone.

Relugolix bụ homonụ na-ahapụ gonadotropin (GnRH) antagonist nke ejiri na ọgwụgwọ ọtụtụ ọnọdụ na-anabata homonụ.Ebu ụzọ kwado ya na Japan na 2019, n'okpuru akara aha Relumina, maka ọgwụgwọ symptomatic nke uterine fibroids, na nso nso a site na United States'FDA na 2020, n'okpuru aha Orgovyx, maka ọgwụgwọ ọrịa kansa prostate dị elu.A mụọkwara Relugolix na ọgwụgwọ mgbaàmà nke endometriosis.Relugolix bụ nke mbụ (na ugbu a naanị) onye na-anabata GnRH na-anabata ọnụ nke akwadoro maka ọgwụgwọ ọrịa kansa prostate - usoro ọgwụgwọ ndị dị ka [degarelix] chọrọ nchịkwa subcutaneous - ya mere na-enye nhọrọ ọgwụgwọ dị obere arọ maka ndị ọrịa nwere ike chọọ nleta ụlọ ọgwụ. maka nchịkwa site n'aka ndị ọkachamara ahụike.Na mgbakwunye na ọ dị mfe iji ya eme ihe, e gosipụtara relugolix ka ọ dị elu na ịda mbà n'obi nke ọkwa testosterone ma e jiri ya tụnyere [leuprolide], usoro ọgwụgwọ ọzọ nke androgen na-eji na-agwọ ọrịa cancer prostate.

Relugolix bụ Gonadotropin na-ahapụ Hormone Nnabata antagonist.Usoro nke relugolix dị ka Gonadotropin Releasing Hormone Receptor Antagonist, na Cytochrome P450 3A Inducer, na Cytochrome P450 2B6 Inducer, na Ọrịa Cancer Resistance Protein Inhibitor, na P-Glycoprotein Inhibitor.Mmetụta physiologic nke relugolix bụ site na mbelata ihe nzuzo GnRH.

Ọdịdị chemical